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Preparation and characterization of simvastatin/DMbCD 
complex and its pharmacokinetics in rats
Simvastatin is poorly bioavailable because it is practically 
insoluble in water and shows dissolution rate-limited ab-
sorption. Solubilizing effects of several b-cyclodextrin (bCD) 
derivatives such as HPbCD, SBEbCD and DMbCD on simva-
statin in aqueous solution were investigated using the phase 
solubility technique. The solubility diagram of simvastatin 
with each bCD derivative could be classified as AL-type, in-
dicating soluble complex formation of 1:1 stoichiometry. 
Among the above bCD derivatives DMbCD was found to be 
the ideal complexing agent for improving drug solubility. 
The simvastatin complex with DMbCD was prepared using 
the co-evaporation method and was then characterized by 
differential scanning calorimetry (DSC), Fourier-transform 
infrared spectroscopy (FT-IR) and in vitro dissolution. Dis-
solution and pharmacokinetic studies indicated that the 
simvastatin/DMbCD complex exhibited an increased disso-
lution rate, rapid absorption, and improved bioavailability 
in rats compared to free drug. Maximum plasma concentra-
tion (cmax) and the time to reach it (tmax) were 21.86 µg mL–1 
and 1.4 h for the drug complex, 8.25 µg mL–1 and 3.0 h for free 
drug, respectively. Main pharmacokinetic parameters such 
as tmax, cmax were significantly different (p < 0.01) between the 
simvastatin complex and free drug. Bioavailability of the 
simvastatin complex relative to free drug was up to 167.0 %.
Keywords: simvastatin, DMbCD, complex, solubility, disso-
lution rate, pharmacokinetics
Simvastatin is a cholesterol lowering agent, which is an inhibitor of 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG-CoA) reductase belonging to the class of statins. It is an inactive 
prodrug that undergoes enzymatic and chemical conversion in the intestine, plasma, and 
liver to the hydroxy acid form of the drug (SVA), the main pharmacologically active 
metabolite. After conversion, SVA acts by decreasing cholesterol synthesis and increasing low 
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prevention of coronary heart diseases; simvastatin is therefore widely used to treat hyper-
cholesterolemia (1). As the drug is practically insoluble in water, it is poorly absorbed from 
the gastrointestinal (GI) tract after oral administration, which results in low bioavailability 
and also poor clinical efficacy (2, 3). Many methods or techniques such as micronization, 
solid dispersion, cyclodextrin complexation, microemulsion, liposomes, nanoparticles, 
phospholipid complex, and self-microemulsifying drug delivery system (SMEDDS), etc. 
have been tried to improve the solubility, dissolution rate and thus oral bioavailability of 
the drug (4–12). 
Cyclodextrins (CDs) are well known molecular entities used as pharmaceutical 
excipients mainly to modulate the physicochemical and pharmaceutical properties of 
some drugs, such as increased solubility and dissolution rate, improved chemical stability 
and bioavailability, reduced toxicity and irritation and controlled rate release (13). In recent 
years, several important derivatives of bCD, such as hydroxypropyl-b-cyclodextrin 
(HPbCD), sulfobutylether-b-cyclodextrin (SBEbCD) and dimethyl-b-CD (DMbCD), have 
gained considerable attention owing to their greater aqueous solubility, higher safety and 
better complexation ability (14–16). Thus, simvastatin complexation with the above water-
soluble bCD derivatives may be an ideal method to solve the problems of poor solubility, 
dissolution rate and thus low oral bioavailability of the drug.
So far, CDs such as αCD, bCD, γCD, randomly methylated-bCD (RMbCD) and HPbCD 
have been reported to be able to form inclusion complexes with simvastatin (17, 18). Further, 
it has been found that the drug/HPbCD complex orally administered to rats displayed 
higher hypolipidemic activity in terms of total cholesterol serum levels compared to free 
simvastatin (19). However, optimal CD complexing excipients for improving the solubility 
and dissolution rate of the drug are unknown and the exact bioavailability of the drug/CD 
complex following oral dosing has not been reported in the literature. Hence, the objective 
of this study was to investigate and compare the solubilizing effects of several derivatives 
of bCD on aqueous solubility of simvastatin. The optimal complexing agent DMbCD was 
then chosen to prepare a simvastatin complex. DSC, FT-IR and dissolution rate studies 
were used to characterize the properties of the drug/DMbCD complex. Pharmacokinetics 
and relative bioavailability of the simvastatin/ DMbCD complex was also evaluated in rats.
EXPERIMENTAL
Materials
Simvastatin of 98.2 % purity was purchased from Jinxin Pharmaceutical Industry Co. 
(China). bCD of 100.0 % purity, HPbCD of 99.0 % purity (degree of substitution 4.9 and 
average molecular weight 1419 Da) and SBEbCD of 99.5 % purity (degree of substitution 
6.2 and average molecular weight 2115 Da) were all purchased from Shandong Xinda Bio-
technology Co., Ltd. (China). DMbCD of 99.6 % purity (degree of substitution 13.0 and 
average molecular weight 1317 Da) was a gift from Binzhou Zhiyuan Biotechnology Co., 
Ltd. (China). The HPLC grade acetonitrile was obtained from Beijing Mreda Technology 
Co., Ltd. (China). All other chemicals and solvents were of analytical reagent grade and 
used as received without further purification. Deionized double-distilled water was used 
throughout.
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Determination of simvastatin content 
Simvastatin content was determined by the reversed-phase high-performance liquid 
chromatography (RP-HPLC) method with minor modifications (20). The HPLC system 
consisted of a LC-20AT pump equipped with a SIL-20A autosampler, a SPD-20A ultraviolet-
visible detector from Shimadzu (Japan). The analysis was performed at room temperature 
on a C18 column (250×4.6 mm i.d., 5.0 µm, Japan). The mobile phase was a mixture of 0.025 
mol L–1 phosphate buffer (pH 4.5) and acetonitrile at a volume ratio of 20/80 (V/V) and was 
pumped at a flow rate of 1.0 mL min–1. The injection volume was 20 µL and the detection 
wavelength was fixed at 238 nm. Quantification was carried out according to the correla-
tion relationship between the chromatographic peak area of the drug (A) and its mass 
concentration (c). The obtained calibration equation (A = 57725c–12919, n = 7) showed good 
linearity over the concentration range of 0.22–21.7 µg mL–1 with the correlation coefficient 
of over 0.9995. The lowest limit of quantification (LLOQ) for drug determination was 
0.22 µg mL–1. Within-day and between-day precisions of the analytical method were both 
lower than 2.0 %. The accuracy of drug determination was found to be 99.43 ± 0.75 % (n = 9).
Phase solubility studies
To investigate and compare the solubilizing effect of several bCD derivatives, such as 
HPbCD, SBEbCD and DMbCD, on simvastatin, phase solubility studies were performed 
according to the method reported by Higuchi and Connors (21). An excess amount of sim-
vastatin was added to 10 mL of aqueous solutions containing increasing concentrations of 
several of the above b-CD derivatives (each from 0 to 10 mmol L–1) and then shaken in 
screw capped glass vials at 37.5 °C for 48 h, the time considered sufficient to reach the 
equilibrium. All the suspensions were withdrawn, filtered through a 0.45 µm syringe filter 
and properly diluted with water and then analyzed for drug content by the RP-HPLC 
method, as reported above. The phase solubility diagram was constructed by plotting the 
drug concentration against the CD concentration. The apparent complexation constant (Kc) 
of the simvastatin complex with each CD was calculated from the linear graph obtained 
by plotting the concentration (mmol L–1) of the drug in the solution versus CD concentra-
tion (mmol L–1) according to the equation: Kc = Slope/[Intercept(1 – Slope)].
Preparation of simvastatin/DMbCD complex 
According to the results of the above phase solubility studies, DMbCD was found to be 
the optimal complexing excipient for solubilizing simvastatin among all the investigated 
CDs. Thus, the drug complex with DMbCD at a 1:1 stoichiometric ratio was prepared by the 
co-evaporation method (22). Accurately weighed simvastatin was dissolved in a minimum 
volume of acetone, while DMbCD was dissolved in a suitable volume of water. After that, the 
drug solution was added dropwise and fully mixed with the DMbCD solution in a mortar. 
The resultant mixture was evaporated at 60 °C to dryness in a vacuum oven. The obtained 
solid was passed through a 100 mesh sieve for further use. A physical mixture of the drug 
with DMbCD in the same molar ratio was prepared by simply mixing the two components.
Confirmation of simvastatin/DMbCD complex
Differential Scanning Calorimetry (DSC) analyses of simvastatin, DMbCD, simvas-
tatin /DMbCD physical mixture (PM ) and simvastatin /DMbCD complex were carried out 
148
F. Gu et al.: Preparation and characterization of simvastatin/DMbCD complex and its pharmacokinetics in rats, Acta Pharm. 68 (2018) 
145–157.
 
on a simultaneous thermal analyzer STA 449 F3 Jupiter® (Netzsch-Gerätebau GmbH, Ger-
many). Samples weighing between 5 and 10 mg were loaded into open aluminum pans and 
placed into the DSC cell. The cell had a nitrogen purge flowing at approximately 20 mL 
min–1. The DSC was used to analyze the samples from 40–200 °C at a 10 °C/min heating 
rate. An indium pan served as reference, and all scans were performed in triplicate. The 
instrument was calibrated before sample analysis using an indium standard.
Fourier-transform infrared (FT-IR) analyses of the samples were performed using a 
Perkin-Elmer Spectrum Two spectrometer (PerkinElmer Corporation, USA). Simvastatin, 
DMbCD, simvastatin /DMbCD PM and simvastatin /DMbCD complex was mixed sepa-
rately with IR grade KBr in the weight ratio of 100:1 for tablet preparation. Final spectra 
were performed in a range of 400–4000 cm–1 with 2 cm–1 resolution. All samples were 
 analyzed in triplicate.
Solubility of simvastatin/DMbCD complex
Solubilities of simvastatin and its DMbCD complex were determined using water or 
pH 7.0 phosphate buffer containing 0.5 % (m/V) SLS as solvents to examine the effect of pH 
and surfactant on drug solubility. An excess amount of samples was added to 5 mL of 
water or the pH 7.0 phosphate buffer in glass test tubes sealed with stoppers. The tubes 
were kept in a thermostatic water bath and shaken at 50 ± 0.5 °C and 50 rpm until reaching 
equilibrium for a period of 48 h. A portion of solution was withdrawn and then filtered 
through a 0.45-µm syringe filter and suitably diluted with the mobile phase. Finally, the 
drug concentration was also analyzed using the above RP-HPLC method.
Dissolution of simvastatin/DMbCD complex
Dissolution studies were conducted using a ZRS-8 intelligence dissolution tester 
(Tianjin, China) based on the 2015 edition of Chinese Pharmacopoeia, apparatus 2 method. 
Powders of simvastatin and its DMbCD complex equivalent to 10 mg of the drug were 
placed in 900 mL of pH 7.0 phosphate buffer thermostatically maintained at 37 ± 0.5 °C, 
using a paddle stirring speed of 100 rpm. At specific time intervals, 5 mL of samples were 
withdrawn and immediately filtered through a 0.45 µm syringe filter. Meanwhile, an equal 
volume of the dissolution medium maintained at 37 ± 0.5 °C was added to keep the dis-
solution medium volume constant. The filtrates were appropriately diluted and subjected 
to drug analysis using the above HPLC method. The results are reported as the cumulative 
percent drug dissolved in three replicates.
Animal experiments 
Pharmacokinetics and bioavailability of the simvastatin/DMbCD complex were per-
formed in comparison with free drug in male Wistar rats (Inner Mongolia University 
 Experimental Animal Center, Hohhot, China), weighing 200–220 g. The study was approved 
by the Institutional Animal Ethics Committee of Affiliated Hospital, Inner Mongolia 
 Medical University. Throughout the experiment, the animals were housed in plastic cages 
on corn-cob bedding at room temperature (25 °C) with a 12 h light/dark cycle. The animals 
were kept in these facilities for at least 1 week before the experiment and fasted for 12 h 
prior to experiments with free access to water. Twelve rats were randomly divided into two 
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groups of six animals each. The test and reference groups were given orally 1 mL 100 g–1 
b.m. of 0.5 % m/V) CMC aqueous suspension containing free simvastatin or its DMbCD 
complex at a dose of 50 mg kg–1 b.m. via gastric gavage needles, respectively. Blood samples 
of 0.5 mL each were withdrawn into 1.5-mL heparinized PE tubes at 0.25, 0.5, 1.0, 1.5, 2.0, 
3.0, 4.0, 5.0, 6.0, 8.0 and 10.0 h following oral dosing by retro-orbital puncture. At the same 
time, an equal volume of 0.9 % normal saline was given intraperitoneally to rats immedi-
ately after each blood sampling. All plasma samples were obtained by centrifuging blood 
samples at 4,000 rpm for 10 min and were stored at –20 °C until HPLC analysis.
Analysis of simvastatin in plasma
Simvastatin in rat plasma was quantified by the HPLC-UV method according to the 
reported method with some modifications (23, 24). Briefly, aliquots of 200 µL plasma were 
pipetted into 5-mL centrifuge tubes, 100 µL of methanol and 20 µL of internal standard 
(5 µg mL–1 lovastatin solution prepared with methanol) were added and vortexed for 2 min. 
Then, 800 µL of cyclohexane was added, vortexed for 30 s and then centrifuged for 10 min 
at 4000 rpm. The organic layer was transferred to clean centrifuge tubes and then evapo-
rated under a gentle nitrogen flow at 45 °C until dryness. The residue was reconstituted with 
400 µL of methanol, vortexed for 60 s and then centrifuged for 10 min at 4000 rpm. Finally, 
20 µL of the supernatant was injected into the HPLC system using an autosampler. Bio-
analysis of simvastatin was performed on a Wondasil C18 column (250×4.6 mm, i.d., 5 µm, 
Japan) with a guard column SuperSustain C18 (10×4.0 mm, i.d., 5 µm, Japan). The mobile 
phase consisted of acetonitrile, water and acetic acid at a volume ratio of 70/30/0.1 (V/V) and 
was set at a flow rate of 1.0 mL min–1. The detection wavelength was fixed at 238 nm. All 
assays were performed at the column temperature of 30 °C. Quantification was performed 
according to the peak area ratio of the drug to internal standard (Y = Adrug /AIS). The obtained 
calibration equation (Y = 0.0339c – 0.0123, n = 7) showed good linearity over the concentra-
tion range of 0.18–36.7 µg mL–1 with the correlation coefficient of over 0.9994. The  lowest 
limit of quantification (LLOQ) for drug determination in rat plasma was 0.367 µg mL–1. 
Accuracy of simvastatin determination in rat plasma was found to be 102.4 ± 4.38 % (n = 9). 
Within-day and between-day precisions of the analytical method were both lower than 
10.0 %. Mean extraction recovery of simvastatin in rat plasma was over 90.0 %.
Pharmacokinetic analysis
Pharmacokinetic analysis was performed by means of a model-independent method 
using the 3P97 pharmacokinetic program issued by the Chinese State Food and Drug 
Administration. The elimination rate constant (Kel) was obtained as the slope of the linear 
regression of the log-transformed plasma concentration values versus time data in the ter-
minal phase. The elimination half-life (t1/2) was calculated as 0.693/Kel. Peak concentration 
(cmax) of the drug in plasma as well as the time to reach it (tmax) were observed as raw data. 
The area under the curve to the last measurable concentration (AUC0-t) was calculated by 
the linear trapezoidal rule. The area under the curve extrapolated to infinity (AUC0-∞) was 
calculated as AUC0-t+ct/Kel, where ct is the last measurable concentration. Analysis and 
comparison of the pharmacokinetic parameters of free simvastatin and its DMbCD com-
plex were performed using the SPSS statistical software (version 22.0, SPSS Inc.). p < 0.05 
was taken as statistically significant.
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Phase solubility studies 
As shown in Fig.1, the solubility of simvastatin increased linearly as a function of CD 
concentration. The phase solubility diagram of simvastatin for each CD follows an AL-
type according to the Higuchi and Connors classification, suggesting the soluble complex 
formation of 1:1 stoichiometry over the concentration range (0–10 mmol L–1) investigated. 
These results are in close agreement with previous reports (19, 25). The apparent complex-
ation constant (Kc) values calculated from the phase solubility diagram were 91895, 53530, 
23564 and 4702 L mol–1 for DMbCD, SBEbCD, HPbCD and bCD complex, respectively. In 
other words, the host-guest molecular interaction forces between simvastatin and CDs 
were in the order: DMbCD > SBEbCD > HPbCD > b-CD, suggesting that the effect of steric 
hindrance of the sulfobutylether group in SBEbCD or the hydropropyl group in HPbCD 
was greater than that of the methyl group in DMbCD (26). Moreover, the solubilizing effect 
of the above CDs on the drug was also in the order: DMbCD > SBEbCD > HPbCD > b-CD. 
When the concentration of each CD was reached at 10 mmol L–1, the drug solubility showed 
approximately a 900-fold increase for DMbCD, 530-fold increase for SBEbCD, 230-fold in-
crease for HPbCD and 80-fold increase for bCD compared to free simvastatin. Thus, 
DMbCD seems to be the ideal complexing agent for solubilizing the drug.
Confirmation of simvastatin/ DMbCD complex
The DSC thermograms of simvastatin, DMbCD, simvastatin/DMbCD (PM), simvas-
tatin /DMbCD complex are given in Fig. 2. Simvastatin was characterized by a sharp melt-
ing endothermic peak at 140.5 °C during DSC analysis and the thermogram of DMbCD 
exhibited a very broad endothermic effect in the temperature range 45–120 °C, which at-
Fig. 1. Phase solubility diagram of simvastatin as a function of CD concentration at 37.5 °C.
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tained a maximum about 90 °C due to the release of water molecules. The DSC curve of 
simvastatin/DMbCD (PM) shows two peaks: a broad endotherm around 90 °C correspond-
ing to the water loss of DMbCD and an endothermal melting peak at 139.5 °C characteristic 
of the drug. For the simvastatin/DMbCD complex, however, the endothermic peak corre-
sponding to the drug almost disappeared and, furthermore, the melting temperature of 
the drug changed to less than 138 °C, probably revealing conversion of simvastatin crystal-
line to amorphous form after complexation by DMbCD. 
The FT-IR spectra of simvastatin, DMbCD, simvastatin/DMbCD (PM) and simvas-
tatin/DMbCD complex are shown in Fig. 3. The characteristic absorption peaks of simvas-
tatin were found at 3545 cm−1 (free O–H stretching vibration), 2970 cm−1 (methyl C–H 
stretching vibration), 1723 and 1696 cm−1 (stretching vibration of C=O for ester and lactone), 
1285 cm−1 (lactone –C–O–C stretching vibration) and the FT-IR spectra of DMbCD showed 
prominent absorption bands at 3415 cm–1 (O–H stretching vibration) and 2940 cm–1 (C–H 
stretching vibration) and 1175 cm–1, 1010 cm–1 (C-H, O–H stretching vibration). In addition, 
the FT-IR spectra of simvastatin/DMbCD (PM) showed no obvious differences from the 
separate spectra of simvastatin and DMbCD, especially as the obvious stretching vibration 
peak of the carbonyl group for the drug still existed. For the FT-IR spectra of the simvas-
tatin/DMbCD complex, however, the characteristic absorption peaks of the carbonyl group 
of the drug in the range of 1600–1800 cm–1 almost disappeared. This can be probably at-
tributed to the complexation of the drug into the DMbCD hydrophobic cavity. The above 
results also indicate that the carbonyl group of lactone ring of simvastatin might be in-
volved in the complexation process (27).
Fig. 2. DSC thermograms of simvastatin, DMbCD, simvastatin/DMbCD (PM) and simvastatin/DMbCD 
complex.
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Solubility of simvastatin/DMbCD complex
The observed solubilities of free simvastatin and its DMbCD complex in distilled 
water or pH 7.0 phosphate buffer containing 0.5 % SLS are shown in Table І. The solubility 
of the drug/DMbCD complex exhibited a 250-fold increase in water, 2.65-fold increase in 
pH 7.0 phosphate buffer containing 0.5 % SLS at 50 ± 0.5 °C compared to free drug. The 
results were very similar to those reported by Aushuman et al. (2). According to the chemical 
Fig. 3. FT-IR spectra of simvastatin, DMbCD, simvastatin/DMbCD (PM) and simvastatin/DMbCD 
complex.
Table І. Solubility of free simvastatin and its DMbCD complex in water and pH 7.0 phosphate buffer 
containing 0.5 % SLS at 50 ± 0.5 °C
Formulations
Solubility (µg mL–1)
Water pH 7.0 phosphate buffer containing 0.5 % SLS
Simvastatin 0.23 ± 0.03 242.5 ± 38.9
Simvastatin/DMbCD complex 57.5 ± 19.3a 641.8 ± 51.5a
Data are represented as mean ± SD (n = 3). a p < 0.01, compared to free drug.
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structure of simvastatin, it seems impossible for the drug to convert to salt forms in water 
or pH 7.0 phosphate buffer. Thus, the obviously increased solubility of free simvastatin in 
pH 7.0 phosphate buffer containing 0.5 % SLS could be primarily attributed to the solubiliz-
ing effect of the surfactant SLS rather than to the effect of medium pH. Since the solubility 
of simvastatin in water was quite low and the solubilizing effect of SLS on the drug, how-
ever, was very significant, the increase in solubility of the simvastatin/DMbCD complex 
was more remarkable in water than in pH 7.0 phosphate buffer containing 0.5 % SLS. In 
other words, the solubilizing effect on the drug of SLS alone seemed to be more prominent 
than that of DMbCD alone. 
Dissolution of simvastatin/DMbCD complex
Fig. 4 shows the dissolution profiles of simvastatin and its DMbCD complex. The 
nearly complete dissolution of simvastatin from the drug/DMbCD complex could be 
reached in 20 min; however, the cumulative dissolution for free drug was less than 40 % at 
the same time, and lower than 80 % in 60 min. Based on the results of our research, the 
notably improved dissolution rate of simvastatin might be attributed to the amorphous 
state, increased wettability of the drug and complex formation with DMbCD in aqueous 
solution (28). 
Pharmacokinetic studies 
The mean plasma concentration-time profiles after intra-gastric administration of the 
simvastatin/DMbCD complex suspension as well as free drug suspension are illustrated 
in Fig. 5, while the main pharmacokinetic parameters of the drug are summarized in Table 
II. From the plasma time profile, very rapid absorption of the drug from the DMbCD com-
plex was observed in rats and tmax was only approximately 1.4 h. In contrast, the maximum 
plasma concentration (cmax) was achieved in about 3.0 h when free drug was given to rats 
Fig. 4. Dissolution profiles of simvastatin (circles) and its DMbCD complex (squares) in pH 7.0 phos-
phate buffer. Data are represented as mean ± SD (n = 3).
154
F. Gu et al.: Preparation and characterization of simvastatin/DMbCD complex and its pharmacokinetics in rats, Acta Pharm. 68 (2018) 
145–157.
 
orally. The above results suggested that simvastatin was more easily dissolved and thus 
absorbed from the drug/DMbCD complex in rats. Furthermore, the obtained cmax for the 
drug complex was found to be approximately 2.5 times higher than that for free drug at a 
dose of 30 mg kg–1. Moreover, the AUC0–∞values were 72.96 ± 39.94 and 43.68 ± 27.14 µg h mL–1 
for the drug complex and free drug, respectively. The bioavailability of the drug/DMbCD 
complex relative to free drug was calculated to be up to 167.0 %, suggesting that complex-
ation of simvastatin by DMbCD resulted in about 1.7-fold higher extent of drug absorption 
than that of free drug. The faster absorption and increased bioavailability of the drug/
DMbCD complex in rats could be probably attributed to the significantly improved aque-
Fig. 5. Mean plasma concentration-time profiles after oral administration of simvastatin/DMbCD 
complex (diamonds) as well as free drug (squares) at the dose of 50 mg kg–1 to rats. Data are repre-
sented as mean ± SD (n = 6).
Table II. Pharmacokinetic parameters of simvastatin/ DMbCD complex in rats using free drug as a control
Parameters Free drug Simvastatin/DMbCD complex
tmax (h) 3.0 ± 0.63 1.42 ± 0.49a
cmax (µg mL–1) 8.25 ± 2.66 21.86 ± 4.89a
t1/2 (h) 3.22 ± 0.96 3.24 ± 1.35b
Kel (h–1) 0.23 ± 0.07 0.25 ± 0.11b
AUC0-t (µg h mL–1) 35.27 ± 16.81 66.20 ± 38.50a
AUC0-∞ (µg h mL–1) 43.68 ± 27.14 72.96 ± 39.94a
Fr (%) 167.0 %
Data are represented as mean ± SD (n = 6). Dose 50 mg kg–1.
a p < 0.01 or 0.05, b p < 0.05, compared to the control. 
AUC0-t – area under the plasma concentration-time curve from time zero to the time of last measured concentra-
tion, AUC0-∞ – area under the plasma concentration-time curve from time zero to infinite, cmax – peak concentration; 
tmax – time to reach peak concentration; t1/2 – elimination half-life; Kel – elimination rate constant.
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ous solubility and rapid dissolution rate of simvastatin due to complexation with DMbCD. 
The results of pharmacokinetic studies were in agreement with those of the pharmacody-
namic studies previously reported by Jun et al. (19), which proved that the simvastatin/
HPbCD complex showed better reduction of total cholesterol and TG levels than free drug 
in rats.
CONCLUSIONS
Phase solubility studies demonstrated that the water-insoluble drug simvastatin with 
several water-soluble bCD derivatives, such as HPbCD, SBEbCD and DMbCD, could be 
able to form a 1:1 stoichiometric complex in water. Among the above CDs, DMbCD was 
found to be the ideal complexing agent for improving the drug solubility and it also exhib-
ited the largest complexation ability with the drug. The co-evaporation method was ap-
plied to prepare the drug complex with DMbCD. DSC and FT-IR suggested conversion of 
the simvastatin crystalline nature to amorphous one and the presence of intermolecular 
hydrogen bonds between the drug and DMbCD. Solubility and dissolution studies indi-
cated that the aqueous solubility and dissolution rate of the drug were obviously enhanced 
compared to free drug. Furthermore, the pharmacokinetic and bioavailability studies con-
firmed that the simvastatin/ DMbCD complex showed faster absorption and higher bio-
availability than free drug in rats. This could be mainly attributed to the enhanced solubil-
ity and increased dissolution due to complexation of the drug with DMbCD. Thus, DMbCD 
will have a potential to be used for enhancement of solubility and dissolution rate, and 
thereby bioavailability of the water-insoluble simvastatin. 
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